|
Barrier Therapeutics, Inc. - Comparative Business Analysis Snapshot
Business Description
Barrier Therapeutics, Inc.. The Group's principal activity is the discovery, development and commercialization of a portfolio of innovative pharmaceutical products to address major medical needs in the field of dermatology. Currently it has multiple product candidates in clinical development, with four of these candidates in or entering Phase III clinical trials. Its advanced product candidates are Sebazole, Zimycan, Hyphanox and Liarozole. Its trademarks are Barrier TherapeuticsTM, SebazoleTM, ZimycanTM, HyphanoxTM, RambazoleTM and HivenylTM. The Group operates in the United States.
Competitor Analysis
This analysis compares Barrier Therapeutics, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
